Literature DB >> 20308366

Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.

F Babakhani1, J Seddon, N Robert, Y-K Shue, P Sears.   

Abstract

The effects of the inoculum, pH, cation concentrations, and different lots of commercial media on the in vitro susceptibility of Clostridium difficile to fidaxomicin were examined. Of the factors evaluated, only pH alterations influenced the activity of fidaxomicin against C. difficile, noticeably reducing its activity at higher pH (> or =7.9).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308366      PMCID： PMC2876407          DOI： 10.1128/AAC.01842-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001.

Authors:  Lennox K Archibald; Shailen N Banerjee; William R Jarvis
Journal:  J Infect Dis       Date:  2004-04-20       Impact factor: 5.226

2.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe.

Authors:  E J Kuijper; B Coignard; J S Brazier; C Suetens; D Drudy; C Wiuff; H Pituch; P Reichert; F Schneider; A F Widmer; K E Olsen; F Allerberger; D W Notermans; F Barbut; M Delmée; M Wilcox; A Pearson; B C Patel; D J Brown; R Frei; T Akerlund; I R Poxton; P Tüll
Journal:  Euro Surveill       Date:  2007-06-01

5.  Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006.

Authors:  Jason Kim; Sarah A Smathers; Priya Prasad; Kateri H Leckerman; Susan Coffin; Theoklis Zaoutis
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

6.  Clostridium difficile: an update on its epidemiology and role in hospital outbreaks in England and Wales.

Authors:  T Djuretic; P G Wall; J S Brazier
Journal:  J Hosp Infect       Date:  1999-03       Impact factor: 3.926

Review 7.  Community-onset Clostridium difficile-associated diarrhoea not associated with antibiotic usage--two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea.

Authors:  M P Bauer; A Goorhuis; T Koster; S C Numan-Ruberg; E C Hagen; S B Debast; E J Kuijper; J T van Dissel
Journal:  Neth J Med       Date:  2008-05       Impact factor: 1.422

8.  In vitro activity of OPT-80 against Clostridium difficile.

Authors:  Grit Ackermann; Birgit Löffler; Daniela Adler; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 9.  Clinical impact and associated costs of Clostridium difficile-associated disease.

Authors:  R C Spencer
Journal:  J Antimicrob Chemother       Date:  1998-05       Impact factor: 5.790

10.  Clostridium difficile infections: emerging epidemiology and new treatments.

Authors:  Mitchell B Cohen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-04       Impact factor: 2.839
View more
  6 in total

1.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Fidaxomicin: a review of its use in patients with Clostridium difficile infection.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

3.  Antimicrobial activities of fidaxomicin.

Authors:  Ellie J C Goldstein; Farah Babakhani; Diane M Citron
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

4.  Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.

Authors:  A M Jarrad; A Debnath; Y Miyamoto; K A Hansford; R Pelingon; M S Butler; T Bains; T Karoli; M A T Blaskovich; L Eckmann; M A Cooper
Journal:  Eur J Med Chem       Date:  2016-04-27       Impact factor: 6.514

Review 5.  Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.

Authors:  Laith A Al Momani; Omar Abughanimeh; Boonphiphop Boonpheng; Joseph Gabriel Gabriel; Mark Young
Journal:  Cureus       Date:  2018-06-11

Review 6.  Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.

Authors:  George G Zhanel; Andrew J Walkty; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Nov-Dec       Impact factor: 2.471
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.